ライフサイエンスコーパス: albuminuria

1 duria, low molecular weight proteinuria, and albuminuria.

2 pression of a highly sulfated HS domain, and albuminuria.

3 ndothelial glycocalyx is required to prevent albuminuria.

4 ne (Kmo) as a candidate gene associated with albuminuria.

5 that included persons with higher eGFRs and albuminuria.

6 een-group difference in the rate of incident albuminuria.

7 ays and highlight novel pathways influencing albuminuria.

8 omerulosclerosis, interstitial fibrosis, and albuminuria.

9 2) and approximately 30% to 40% reduction in albuminuria.

10 lbumin in urine for the diagnoisis of (micro)albuminuria.

11 y, or death from renal disease) and incident albuminuria.

12 capillary rarefaction in the pathogenesis of albuminuria.

13 in eGFR and a greater reduction of residual albuminuria.

14 Residual risk is related to residual albuminuria.

15 acute and chronic kidney diseases by GFR and albuminuria.

16 tion but had no effect on the development of albuminuria.

17 No subjects exhibited elevated levels of albuminuria.

18 by different levels of glycaemic control and albuminuria.

19 a graded fashion, and so was the presence of albuminuria.

20 jury despite having no effect on established albuminuria.

21 e in eGFR and/or the presence of significant albuminuria.

22 plasma levels are not sufficient to engender albuminuria.

23 maladaptive response to hyperfiltration and albuminuria.

24 ease in nephrin expression and a decrease in albuminuria.

25 patients with type 2 diabetes and prevalent albuminuria.

26 rmance standards and can be used to rule out albuminuria.

27 PKC-alpha is involved in the development of albuminuria.

28 urine suPAR correlated with proteinuria and albuminuria.

29 adriamycin and attenuated the development of albuminuria.

30 No association was seen with albuminuria.

31 optosis and attenuates glomerular injury and albuminuria.

32 meliorate Ang II-induced podocyte injury and albuminuria.

33 months of age or a difference in LPS-induced albuminuria.

34 by glycosuria, aminoaciduria, calciuria, and albuminuria.

35 n, decreasing glomerular hyperfiltration and albuminuria.

36 e and correlate with renal calcification and albuminuria.

37 farction (13% [0-24]), stroke (22% [10-32]), albuminuria (10% [3-16]), and retinopathy progression (1

38 11.8 mL/min/1,73 m2) and a low prevalence of albuminuria (16.9%).

39 .16 [95% CI 1.55-3.01]) and in those with no albuminuria (3.38 [2.51-4.57]), but not in the subgroup

40 showed persistent glomerular hyalinosis and albuminuria 96 hours after injection, whereas wild-type

41 In the absence of albuminuria, age-related reduction in GFR with the corre

42 r filtration rate [eGFR] <60 mL/min/1.73m2), albuminuria (albumin/creatinine ratio >/=3 mg/mmol), and

43 y-induced glomerular injury, as assessed via albuminuria, although the degree of microscopic hematuri

44 heterozygous Cav2.2(+/-) mice also decreased albuminuria, although they exhibited comparable systolic

45 showed that administration of AS-IV reduced albuminuria, ameliorated changes in the glomerular and t

46 cific plexinA1 deletion markedly ameliorates albuminuria and abrogates renal insufficiency and the di

47 y disease, with a strong association between albuminuria and amputation.

48 ut not of the G0 allele, develop functional (albuminuria and azotemia), structural (foot-process effa

49 In multivariable analyses adjusted for albuminuria and cardiovascular risk factors, a baseline

50 rted renal benefits, including inhibition of albuminuria and cellular crescent formation, similar to

51 cell injury explains the association between albuminuria and COPD, (2) CS-induced albuminuria is link

52 etic eNOS(-/-) mice significantly attenuated albuminuria and diabetic kidney injury, which were assoc

53 eserved in MC1R-null mice, marked by reduced albuminuria and diminished histologic signs of podocyte

54 antially milder kidney disease, with minimal albuminuria and dysfunction, compared with vehicle-treat

55 APOL1 risk alleles had the highest risk for albuminuria and eGFRcys decline in young adulthood, wher

56 P domain protein suppressed diabetes-induced albuminuria and enhanced M2 marker expression.

57 rrelate the placebo-corrected drug effect on albuminuria and ESRD to more reliably delineate the asso

58 delineate the association between changes in albuminuria and ESRD.

59 nduced hypertrophy, mesangial expansion, and albuminuria and failed to activate the mammalian target

60 hannel blocker SKF96365 markedly ameliorated albuminuria and glomerular damage in response to DOCA.

61 betes (T2D), which correlates with increased albuminuria and glomerular damage.

62 ction of mice with recombinant Cat-S induced albuminuria and glomerular endothelial cell injury in a

63 IDOL-induced dyslipidemia worsened albuminuria and glomerular macrophage accumulation but h

64 kout (KO) mice with diabetes developed worse albuminuria and glomerular pathology.

65 ice with Cat-S or PAR2 inhibitors attenuated albuminuria and glomerulosclerosis (indicators of diabet

66 d mice immunized with alpha3NC1 developed no albuminuria and had lower levels of serum IgG anti-alpha

67 s of these 5 genes correlated with increased albuminuria and histological measures of renal injury.

68 channel TRPC5 is an important determinant of albuminuria and identify TRPC5 inhibition as a therapeut

69 deletion of Drp1 in diabetic mice decreased albuminuria and improved mesangial matrix expansion and

70 lcium channel blocker, showed a reduction in albuminuria and improvement of glomerular changes compar

71 n wild-type mice resulted in less pronounced albuminuria and increased creatinine clearance.

72 i-miR-92a after disease initiation prevented albuminuria and kidney failure, indicating miR-92a inhib

73 examined associations of APOL1 with incident albuminuria and kidney function decline among 3030 young

74 redispose animals to hypertension-associated albuminuria and kidney injury.

75 hich correlated with variations in levels of albuminuria and known predisposition to progressive neph

76 HBPM, ABPM, and organ damage as measured by albuminuria and left ventricular mass.

77 HBPM, ABPM, and organ damage as measured by albuminuria and left ventricular mass.

78 but EGFR(podKO) mice had significantly less albuminuria and less podocyte loss compared with WT diab

79 1 in diabetic mice caused a 70% reduction of albuminuria and prevented diabetes-induced glomerular en

80 dney disease, and adverse events, as well as albuminuria and progression of retinopathy in trials don

81 cation, which was positively associated with albuminuria and progressive renal function deterioration

82 feriprone significantly delayed the onset of albuminuria and reduced blood urea nitrogen concentratio

83 e determined whether canagliflozin decreases albuminuria and reduces renal function decline independe

84 f EVR with early CNI withdrawal after HTx on albuminuria and renal function seem dissociated; hence,

85 es available, no significant associations of albuminuria and retinal vessel diameters with depression

86 FHL2(+/+) mice developed markedly increased albuminuria and thickening of the glomerular basement me

87 Albuminuria and tubular atrophy are among the highest ri

88 loss, whereas Pod-ETRKO mice presented less albuminuria and were completely protected from glomerulo

89 , 2.6; 95% CI, 1.8 to 3.8, respectively) and albuminuria and/or eGFR<60 ml/min per 1.73 m(2) (OR, 2.9

90 haemoglobin, serum uric acid, serum albumin, albuminuria, and C reactive protein as non-GFR determina

91 Classification of CKD according to GFR, albuminuria, and cause, may improve the management of pa

92 njury substantially reduced talin1 cleavage, albuminuria, and foot process effacement.

93 However, serum creatinine concentration, albuminuria, and glomerular expression of ETS-1 and two

94 nd podocytes leads to defects and depletion, albuminuria, and glomerulosclerosis.

95 s-induced endothelial injury, podocyte loss, albuminuria, and glomerulosclerosis.

96 nant-negative Orai1 mutant (E108Q) increases albuminuria, and in vivo injection of BTP2 exacerbates a

97 atment also improved renal function, reduced albuminuria, and inhibited expression of profibrotic mar

98 d with a marked reduction in renal fibrosis, albuminuria, and nephrinuria.

99 nd prevented the development of proteinuria, albuminuria, and nephrinuria.

100 on, glomerular basement membrane thickening, albuminuria, and podocyte dropout.

101 o losartan, Ly normalized blood pressure and albuminuria, and prevented CKD progression more effectiv

102 /1 to 6 mm Hg), extracellular fluid volume, albuminuria, and proteinuria in patients with moderate-t

103 ependently associated with renal impairment, albuminuria, and proximal renal tubular dysfunction.

104 heart failure, retinopathy, new or worsening albuminuria, and renal failure.

105 resulted in reduced serum creatinine level, albuminuria, and renal histologic changes (mesangial exp

106 7 to -0.24 mL/min/1.73m2/year) and worsening albuminuria (aOR = 2.3; 95% CI = 1.3-4.0).

107 .1; 95% confidence interval [CI] = 1.0-4.4), albuminuria (aOR = 5.8; 95% CI = 3.7-9.0), and proximal

108 Podocyte injury and resulting albuminuria are hallmarks of diabetic nephropathy, but t

109 ated concentrations of albumin in the urine, albuminuria, are a hallmark of diabetic kidney disease a

110 ed with the combination of baseline eGFR and albuminuria (area under the curve [AUC]=0.758), the addi

111 Multivariable analyses confirmed eGFR and albuminuria as key risk factors for predicting adverse a

112 mean serum creatinine concentration and less albuminuria, as well as less histologic evidence of glom

113 etermined with a single urine collection for albuminuria assessment per study visit.

114 ng everolimus (EVR), but the significance of albuminuria associated with EVR treatment after early CN

115 in of type IV collagen (alpha3NC1) developed albuminuria associated with granular capillary loop depo

116 phenotypically normal at birth but developed albuminuria at about 2 weeks of age.

117 -years, reported ESRD outcomes, and measured albuminuria at baseline and during follow-up.

118 is cohort with oversampling of subjects with albuminuria at baseline, urinary potassium excretion was

119 it was also associated with the presence of albuminuria at the time of transplantation.

120 2014) with baseline measurements of eGFR and albuminuria, at least 1000 participants (this criterion

121 nt, but guidelines require that diagnosis of albuminuria be based on at least 2 of 3 samples collecte

122 Albuminuria, but not estimated glomerular filtration rat

123 developed signs of renal disease, including albuminuria by 6 weeks and focal podocyte foot process e

124 resulted in nephritic urine by dipstick and albuminuria by enzyme-linked immunosorbent assay, and mo

125 unction of the renal microcirculation causes albuminuria by increasing glomerular capillary wall perm

126 minuria (increase >/=10%/year with change in albuminuria category).

127 people with GFR 45-59 ml/min/1.73 m2 and no albuminuria (CKD G3aA1).

128 Albuminuria class transition (normo- to micro- to macroa

129 rences in the other variables used to define albuminuria class transition altered the average drug ef

130 giotensin-aldosterone system intervention on albuminuria class transition in patients with diabetes:

131 The definition of albuminuria class transition used in each trial differed

132 HR 1.29, 95% CI 1.19-1.39) of transitions in albuminuria classes.

133 ely to experience eGFR decline and worsening albuminuria compared with HIV-uninfected individuals.

134 increased risk of CKD, decline in eGFR, and albuminuria, compared with noncarriers.

135 eGFR and albuminuria contributed multiplicatively (eg, adjusted H

136 er, only Podo-GC-A KO mice developed massive albuminuria (controls: 35-fold; KO: 5400-fold versus bas

137 that treatment-induced short-term changes in albuminuria correlate with risk change for ESRD.

138 t of the metabolic syndrome and reduction of albuminuria could help to more consistently reach the bl

139 Albuminuria could identify patients with COPD in whom an

140 GN (i.e., vascular necrosis, podocyte loss, albuminuria, cytokine induction, recruitment or activati

141 nge significantly, whereas the prevalence of albuminuria declined and the prevalence of reduced eGFR

142 However, the prevalence of albuminuria decreased progressively over time from 20.8%

143 Furthermore, CSD improved protein and albuminuria, decreased [Ca(2+) ]i evoked responses from

144 m2 at baseline or follow-up), incident CKD, albuminuria (defined as a spot urine albumin:creatinine

145 ic deletion of GLUT4 (G4 KO) did not develop albuminuria despite having larger and fewer podocytes th

146 renal nephrin phosphorylation and attenuated albuminuria development independently of glucose change.

147 he sera of patients with type 1 diabetes and albuminuria (DKD(+)) when compared with diabetic patient

148 Yet, there was no net albuminuria due to binding and uptake of filtered albumi

149 m restriction substantially reduced residual albuminuria during fixed dose angiotensin-converting enz

150 Reduction of residual albuminuria during single-agent renin-angiotensin-aldost

151 8%] vs 1168 of 5947 noncarriers [19.6%]) had albuminuria during the study period.

152 data show that declining eGFR and increasing albuminuria each independently increase hemorrhage risk.

153 tors with and without creatinine-based eGFR, albuminuria (either albumin-to-creatinine ratio [ACR] or

154 Albuminuria, even at low levels, is associated with adve

155 elective PT cell defects lead to significant albuminuria, even reaching nephrotic range in animal mod

156 doplasmic reticulum, resulted in progressive albuminuria, foot process effacement, and histology cons

157 imated glomerular filtration rate (eGFR) and albuminuria for prediction of cardiovascular outcomes is

158 the requirement of a percentage increase in albuminuria from baseline in addition to the class trans

159 equirement of a minimal percentage change in albuminuria from baseline seems unnecessary.

160 urements of blood pressure, BUN, creatinine, albuminuria, genotyping and immunoblotting, this APOL1 n

161 In the intention-to-treat analysis, albuminuria (geometric mean) was 1060 (95% confidence in

162 apamil attenuated hHcys-induced proteinuria, albuminuria, glomerular damage, and podocyte injury.

163 ity lipoprotein cholesterol, hemoglobin A1c, albuminuria, glomerular filtration rate, smoking, and ex

164 ervention with a NOX1/NOX4 inhibitor reduced albuminuria, glomerular hypertrophy, and mesangial matri

165 We here show that the Elmo1 hypermorphs have albuminuria, glomerulosclerosis, and changes in the ultr

166 ndrial-targeted ROS prevented podocyte loss, albuminuria, glomerulosclerosis, and renal failure.

167 sex, higher baseline serum creatinine value, albuminuria, greater severity of acute kidney injury, an

168 on estimated GFR <60 mL/minute/1.73m(2) and albuminuria >/=30 mg/g.

169 CKD-Epidemiology Collaboration equation, or albuminuria >30 mg/g, and CKD stages 3-5 was defined as

170 patients with nondiabetic CKD stages 1-3 and albuminuria >300 mg/24 h despite ramipril at 10 mg/d and

171 ld with CKD (eGFR<60 ml/min per 1.73 m(2) or albuminuria>/=30 mg/g) not on dialysis.

172 cohort of 1738 patients with CKD showed that albuminuria>/=300 mg/24 hours is predictive of higher ph

173 Albuminuria has been proposed as a surrogate end point i

174 While albuminuria has been shown to injure renal proximal tubu

175 hat decreased glomerular filtration rate and albuminuria have different roles in brain structure alte

176 gliflozin with respect to the progression of albuminuria (hazard ratio, 0.73; 95% CI, 0.67 to 0.79) a

177 Among participants with albuminuria, high DAL was strongly associated with ESRD

178 Adjusting for eGFR and albuminuria, however, completely attenuated the associat

179 l role in promoting podocyte dysfunction and albuminuria, however, the underlying mechanisms have not

180 etion of iPLA2gamma did not cause detectable albuminuria; however, it resulted in mitochondrial struc

181 c]; P < .001), as well as the development of albuminuria (HR = 2.20 [95% CI, 1.46-3.31]; P < .001).

182 estimated glomerular filtration rate, higher albuminuria, hypertension, current or former smoking, di

183 flozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renopro

184 ), as assessed with skin capillaroscopy, and albuminuria in 741 participants of the Maastricht Study,

185 ly suppressed diabetic glomerular injury and albuminuria in both WT and miR-146a(-/-) animals.

186 ) and dietary sodium restriction on residual albuminuria in CKD.

187 eliorated diabetes-mediated renal damage and albuminuria in Cyp4a14KO male mice.

188 Albuminuria in maintenance heart transplantation (HTx) i

189 olesterol depletion was sufficient to reduce albuminuria in mice with podocyte-specific NFATc1 activa

190 Experts recommend screening for albuminuria in patients at risk for kidney disease.

191 rm and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and establi

192 er-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type 2 diabetes and prevale

193 as well as blood pressure, body weight, and albuminuria in people with diabetes.

194 841K/E1841K) mice exhibited mildly increased albuminuria in response to high salt; severe albuminuria

195 a, and in vivo injection of BTP2 exacerbates albuminuria in streptozotocin-induced and Akita diabetic

196 ociated; hence, the clinical significance of albuminuria in this setting is uncertain and should not

197 Furthermore, the prevention of albuminuria in treated mice was associated with preserva

198 eceptor antagonist, has been shown to reduce albuminuria in type 2 diabetes.

199 whether pentoxifylline (PTF), which reduces albuminuria, in addition to renin-angiotensin system (RA

200 Primary outcomes were incident CKD, incident albuminuria, incident cardiovascular disease, and all-ca

201 Initial assessment of albuminuria includes measuring urine albumin and creatin

202 iated with greater eGFR decline or worsening albuminuria (increase >/=10%/year with change in albumin

203 In STZ-diabetic mice, albuminuria, increased Src pTyr-416, TACE activation, ER

204 ive pulmonary disease (COPD) frequently have albuminuria (indicative of renal endothelial cell injury

205 Albuminuria is a hallmark of kidney disease of various e

206 Albuminuria is a marker of endothelial dysfunction and h

207 Albuminuria is a well known risk factor for cardiovascul

208 in risk of retinopathy, microalbuminuria, or albuminuria is due to elements of glycemia not captured

209 ssociation between capillary rarefaction and albuminuria is lacking.

210 between albuminuria and COPD, (2) CS-induced albuminuria is linked to increases in the oxidative stre

211 The assessment of albuminuria is needed to improve our ability to identify

212 If confirmation of albuminuria is required because of diurnal variation or

213 The presence of albuminuria is strongly associated with progression of c

214 rolimus treatment resulted in a reduction of albuminuria; its discontinuation restored albuminuria to

215 Our data indicate that albuminuria/lipiduria enhances lipotoxin delivery to the

216 Albuminuria may be a biomarker of generalized (i.e., mic

217 These findings suggest albuminuria may be a valid substitute for ESRD in many c

218 omes has encouraged a reconsideration of how albuminuria may occur in diabetes and how increased urin

219 Median time to first albuminuria measurement was 6 months.

220 ion: plasma markers of endothelial function, albuminuria, measurements of skin and muscle microcircul

221 ney disease, as expression of GqQ>L promoted albuminuria, mesangial expansion, and increased glomerul

222 d wild-type mice, characterized by increased albuminuria, mesangial expansion, glomerular matrix depo

223 brachiuric) ob/ob mice was safe and reduced albuminuria, mesangial expansion, kidney weight, and cor

224 albuminuria in response to high salt; severe albuminuria, nephrinuria, FSGS, and podocyte foot efface

225 This was accompanied by marked albuminuria, nephromegaly, hyperfiltration, glomerular u

226 APA-KO mice developed a significant rise in albuminuria not observed in AngII-treated wild-type mice

227 nteraction), with a decreasing prevalence of albuminuria observed only among adults younger than 65 y

228 Progressive albuminuria occurred in Gsalpha-deficient mice.

229 0 copies) were significantly associated with albuminuria (odds ratio [OR], 3.2; 95% confidence interv

230 eak reactive hyperemia had an odds ratio for albuminuria of 2.27 (95% confidence interval, 1.07 to 4.

231 There were no changes in renal function or albuminuria or blood pressure, although glycated hemoglo

232 Sickle cell trait was also associated with albuminuria (OR, 1.86 [95% CI, 1.49-2.31]; ARD, 12.6% [9

233 0 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6-22.1) for high-

234 End points were annual change in eGFR and albuminuria over 2 years of follow-up.

235 recipient age (P < 0,001), mGFR (P = 0.037), albuminuria (P < 0.001), and metabolic syndrome (P = 0.0

236 abetic kidney disease, defined as persistent albuminuria, persistent reduced eGFR, or both, did not s

237 Nox5(pod+) mice exhibited early onset albuminuria, podocyte foot process effacement, and eleva

238 exhibited significantly increased levels of albuminuria, podocyte injury, and loss of podocytes comp

239 herapy group subjects showing retinopathy or albuminuria progression by EDIC Study year 10) vs. 31 co

240 ffects in WT mice, diabetes did not increase albuminuria, proteinuria, serum cystatin C, or serum cre

241 crocirculation independently associated with albuminuria, providing direct support for a role of capi

242 ity across trials in the treatment effect on albuminuria (range, -1.3% to -32.1%) and ESRD (range, -5

243 In RARE-lacZ transgenic mice, albuminuria reduced retinoic acid bioavailability and im

244 iabetes (95% CI, 6.5-9.9 million adults) had albuminuria, reduced eGFR, or both.

245 ats develop type 2 diabetic nephropathy with albuminuria, reduced glomerular filtration, activation o

246 emapticap pegol (NOX-E36) shows long-lasting albuminuria-reducing effects in diabetic nephropathy.

247 h study medication, PARI did provide further albuminuria reduction (P=0.04 LS + PARI versus LS + PLAC

248 tio, C-reactive protein, angiotensin II, and albuminuria reduction and with increased glucose disposa

249 on and was linked with glomerular matrix and albuminuria reduction in the diabetic kidney.

250 enal fibrosis, hypertrophy, proteinuria, and albuminuria relative to diabetic wild-type mice.

251 ver, mean serum creatinine concentration and albuminuria remained lower in ES allograft recipients th

252 as evidenced by dose-dependent decreases in albuminuria, renal lesions (mesangial expansion, leukocy

253 0.64-0.83]; ARR, 4.06 [95% CI, 2.53-5.40]), albuminuria (RR, 0.83 [95% CI, 0.79-0.87]; ARR, 9.33 [95

254 Creatinine-based eGFR and albuminuria should be taken into account for cardiovascu

255 hat the placebo-adjusted treatment effect on albuminuria significantly correlated with the treatment

256 eks of age led to a significant reduction in albuminuria, similar to that observed with renin-angiote

257 at target: glycohemoglobin, blood pressure, albuminuria, smoking, and low-density lipoprotein choles

258 ntermediate renal outcomes of transitions in albuminuria stages (ie, transitions between normoalbumin

259 agliflozin group versus placebo according to albuminuria status at baseline (normoalbuminuria: UACR <

260 albumin excretion, irrespective of patients' albuminuria status at baseline.

261 lar disease, according to patients' baseline albuminuria status.

262 In contrast, albuminuria strongly associated with all-cause mortality

263 s, animals expressing GqQ>L exhibited robust albuminuria, structural features of FSGS, and reduced nu

264 nt effect on ESRD: for each 30% reduction in albuminuria, the risk of ESRD decreased by 23.7% (95% co

265 estimated glomerular filtration rate, (micro)albuminuria, the use of lipid-modifying and blood pressu

266 001 versus RS + PLAC), and LS + PARI reduced albuminuria to 683 (95% confidence interval, 502 to 929)

267 LS + PLAC reduced albuminuria to 717 (95% confidence interval, 512 to 1005

268 of albuminuria; its discontinuation restored albuminuria to the initial levels.

269 ss the addition of creatinine-based eGFR and albuminuria to traditional risk factors for prediction o

270 In conclusion, the optimal albuminuria transition end point for use in drug interve

271 .9%), fast glycemia and glycated hemoglobin, albuminuria, triglycerides and uric acid levels, and wor

272 ccelerated development of glomerulopathy and albuminuria upon streptozotocin (STZ)-induced hyperglyce

273 Albuminuria, urinary markers of tubule damage (kidney in

274 Albuminuria (urine albumin-to-creatinine ratio >/=30 mg/

275 ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64-8.94) for high-risk blacks an

276 TNF-induced albuminuria was aggravated in mice with podocyte-specifi

277 Albuminuria was also associated with cortical thinning,

278 n (rise in plasma creatinine concentration); albuminuria was also greatly reduced.

279 The associated reduction in albuminuria was also reversible, compatible with a tacro

280 analysis for cortical thickness showed that albuminuria was associated with frontal thinning partial

281 Albuminuria was associated with global longitudinal stra

282 cant heterogeneity in the temporal trend for albuminuria was noted by age (P = .049 for interaction)

283 Albuminuria was reduced in the heparanase-deficient mice

284 Urinary albumin-to-creatinine ratio (albuminuria) was calculated in milligrams per gram with

285 the pathophysiological mechanisms underlying albuminuria, we conducted meta-analyses of genome-wide a

286 the estimated glomerular filtration rate and albuminuria were also analyzed.

287 Estimated GFR (eGFR) and albuminuria were followed up to 5 years posttransplantat

288 Limitation: Serum creatinine and albuminuria were measured only once in each person.

289 and urea, decreased creatinine clearance and albuminuria) were progressively ameliorated as Tgfb1 exp

290 receptor type 2 (CCR2), could further reduce albuminuria when given in addition to standard care, inc

291 antitative POC test result does not rule out albuminuria, whereas quantitative POC testing meets requ

292 ms for CKD account for both reduced eGFR and albuminuria; whether each measure associates with greate

293 e did not develop lipopolysaccharide-induced albuminuria, which requires mTOR activation.

294 Overall, 57 participants had albuminuria, which was defined as a urinary albumin excr

295 ion for the clinical observations of reduced albuminuria with atrasentan in diabetic nephropathy.

296 Previously we demonstrated massive albuminuria with hypertension in uninephrectomized, aldo

297 ial-specific Epas1 gene deletion accentuated albuminuria with severe podocyte lesions and recruitment

298 imated glomerular filtration rate [eGFR] and albuminuria) with the incidence of peripheral artery dis

299 e with the mouse-specific NOX-E36 attenuated albuminuria without any change in systemic hemodynamics,

300 trophy, accumulation of matrix proteins, and albuminuria without changing blood glucose levels.